December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

84.56 -0.23 (-0.27%)
Streaming Delayed Price Updated: 11:31 AM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches and several pivotal data readouts
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
From Biogen Inc.
Via GlobeNewswire
News headline image
Biogen Completes Acquisition of Alcyone Therapeutics
From Biogen Inc.
Via GlobeNewswire
News headline image
DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis reports third quarter 2025 financial results and highlights progress on key programs
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to hold third quarter 2025 financial results webcast
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen
From Biogen Inc.
Via GlobeNewswire
News headline image
Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates
From Biogen Inc.
Via GlobeNewswire
News headline image
Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to host investors and analysts for Innovation Day 2025
From Ionis Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ionis to present at upcoming investor conferences
From Ionis Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.